Certolizumab pegol for the treatment of Crohn's disease
WJ Sandborn, BG Feagan, S Stoinov… - New England journal …, 2007 - Mass Medical Soc
Background Certolizumab pegol is a pegylated humanized Fab′ fragment that binds tumor
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …
Certolizumab pegol for the treatment of Crohn's disease.
WJ Sandborn, BG Feagan, S Stoinov… - The New England …, 2007 - europepmc.org
Methods In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of
certolizumab pegol in 662 adults with moderate-to-severe Crohn's disease. Patients were …
certolizumab pegol in 662 adults with moderate-to-severe Crohn's disease. Patients were …
[引用][C] Certolizumab pegol for the treatment of Crohn's disease
S WJ - N Engl J Med, 2007 - cir.nii.ac.jp
Certolizumab pegol for the treatment of Crohn's disease | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡颏丹す 大学 …
研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡颏丹す 大学 …
[引用][C] Certolizumab pegol for the treatment of crohn's disease
WJ SANDBORN, BG FEAGAN… - The New England …, 2007 - pascal-francis.inist.fr
Certolizumab pegol for the treatment of crohn's disease CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
[引用][C] Certolizumab pegol for the treatment of Crohn's disease
WWJ Sandborn, A Van Gossum - The New England journal of …, 2007 - difusion.ulb.ac.be
Certolizumab pegol for the treatment of Crohn's disease
WJ Sandborn, BG Feagan, S Stoinov… - … England Journal of …, 2007 - researchers.mq.edu.au
Background: Certolizumab pegol is a pegylated humanized Fab'fragment that binds tumor
necrosis factor α. Methods: In a randomized, double-blind, placebo-controlled trial, we …
necrosis factor α. Methods: In a randomized, double-blind, placebo-controlled trial, we …
Certolizumab pegol for the treatment of Crohn's disease.
WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball… - 2007 - bhsdlib.intersearch.com.au
Background Certolizumab pegol is a pegylated humanized Fab′ fragment that binds tumor
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …
Certolizumab pegol for the treatment of Crohn's disease
WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball… - 2007 - pubmed.ncbi.nlm.nih.gov
Background Certolizumab pegol is a pegylated humanized Fab'fragment that binds tumor
necrosis factor alpha. Methods In a randomized, double-blind, placebo-controlled trial, we …
necrosis factor alpha. Methods In a randomized, double-blind, placebo-controlled trial, we …
[PDF][PDF] Certolizumab Pegol for the Treatment of Crohn's Disease
WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball… - N Engl J …, 2007 - researchgate.net
Certolizumab Pegol for the Treatment of Crohn's Disease Page 1 original article The new
england journal of medicine n engl j med 357;3 www.nejm.org july 19, 2007 228 …
england journal of medicine n engl j med 357;3 www.nejm.org july 19, 2007 228 …
Certolizumab pegol for the treatment of Crohn's disease.
WJ Sandborn, BG Feagan, S Stoinov, PJ Honiball… - 2007 - bhsdigitalrepository.bhs.org.au
Background Certolizumab pegol is a pegylated humanized Fab′ fragment that binds tumor
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …
necrosis factor α. Methods In a randomized, double-blind, placebo-controlled trial, we …